Cancer costs money in every health system: bills and insurance payments in some countries, and lost wages and travel costs even where treatment is free. Your team should ask about money early, because help exists and is often missed: a social worker, financial counsellor or benefits adviser can check what you can claim. Money trouble can lead people to skip medicines, so it is part of your care.
ESMO's 2024 expert consensus (19 experts, 11 countries, 25 statements) is the only society statement found that covers screening and management across health systems. It asks for a preliminary assessment of financial impact at diagnosis or before treatment (LoE: V), suggests a sequential strategy of a single screening question followed by a longer validated questionnaire such as COST (11 scored items, 0 to 44, lower is worse), and calls it ethically and medically reasonable to offer financial counselling from a dedicated professional such as a social worker after a positive screen (LoE: III). ASCO's 2009 guidance statement recognised discussion of the cost of care as a component of high-quality care. Most of the evidence is weak: ESMO's practice statements are graded III to V.
What the money problem is differs by system. In the United States it is led by out-of-pocket medical costs: the NCI summary reports cancer survivors 2.7 times more likely to file for bankruptcy, and that fewer than one third of patients have had a cost discussion. In publicly funded systems it is led by lost income and non-medical costs: a systematic review of 32 studies found lost income of 17.6 to 67.3 per cent and out-of-pocket costs of US$17 to US$506 a month, and a UK scoping review found no study using a validated measure. The response differs to match: financial navigation in the United States, benefits and welfare rights advice in the United Kingdom.
Whether these services work is less clear than whether the problem exists. In the CAFE randomised trial (371 people newly diagnosed, two US health systems) proactive financial navigation did not improve financial hardship or quality of life at 12 months against enhanced usual care; a meta-analysis found no significant pooled change in COST score but an effect in people with the worst scores at entry. This page describes what guidelines and studies say; a person's own team, and the benefits rules of their own country, come first.
Why: ESMO says financial toxicity may be more likely close to diagnosis, while people are having their first treatment, though it adds that the evidence is not consistent (LoE: III).
“Health care providers should make a preliminary assessment of financial impact of disease and treatment on the patient and their household at diagnosis or before the start of treatment.”
Why: A simple question can prompt a closer look, and the fuller assessment shows which part of life is affected, so help can be tailored. ESMO calls this a reasonable approach that still needs validation.
“If screening is positive, it should be followed by an in-depth assessment of financial distress faced by the patient to identify which domain is impacted and lead to appropriate, tailored intervention.”
ESMO (ESMO Open; Carrera et al.) 2024 · discussion of Statement 4 (LoE: V)
Why: ASCO, writing about the United States, calls these discussions an important part of high-quality care. The NCI summary reports that about 60 per cent of people across studies had positive attitudes to talking about cost, while fewer than one third had had such a discussion.
“It also recommends that the following steps be taken to address immediate needs: recognition that patient-physician discussions regarding the cost of care are an important component of high-quality care; the design of educational and support tools for oncology providers to promote effective communication about costs with patients; and the development of resources to help educate patients about the high cost of cancer care to help guide their decision making regarding treatment options.”
ASCO, Journal of Clinical Oncology (Meropol et al.) 2009 · ASCO guidance statement, ungraded
Why: People under financial strain sometimes stretch or stop their medicines without saying so, and the team can only help if it knows.
Common practice: No guideline read states this question as a step. It follows from the evidence the NCI summary reports: retrospective studies link financial distress to reduced adherence to planned therapies, and in one survey of 300 patients 27 per cent reported not taking medication as prescribed.
Why: ESMO gives the reason as reducing costs for patients and for whoever pays for the care.
“Clinicians are advised to ‘choose wisely’ and avoid low-value diagnostics and therapeutics, to reduce costs for patients and/or payers: examinations that are not essential to the treatment plan should be discouraged.”
Why: Entitlements differ by country, so ESMO asks for someone who knows the local system thoroughly. It says counselling might produce benefit, which is a cautious claim.
“Counselling should be given by a dedicated professional (like a social worker) who can assess the patient’s economic situation, knows thoroughly the social security system of the jurisdiction and is aware of modalities to help the patient in his/her economic situation.”
ESMO (ESMO Open; Carrera et al.) 2024 · LoE: III
Why: ESMO says benefits are often not used in full because people do not know what they are entitled to or because applying is difficult and slow. It writes this in its discussion of care near the end of life, about the whole course of the illness.
“In many instances, social welfare benefits are not optimized because of lack of knowledge regarding available entitlements, or difficulties and delays in application.”
ESMO (ESMO Open; Carrera et al.) 2024 · discussion of Statement 10 (LoE: III)
Why: ESMO says that most studies suggest it is difficult for income to return to what it was before diagnosis. Its statement on return-to-work plans and adjustments at work is addressed to governments and employers; no source read sets out what the clinic should do.
“Patient access to paid leave can help decrease financial hardship, thereby leading to improved health, better QoL and reduced stress.”
ESMO (ESMO Open; Carrera et al.) 2024 · discussion of Statement 13A (LoE: III)
Why: Costs rise near the end of life, and relatives who are caring often lose income at the same time.
“Because of the high prevalence of financial distress among patients with far advanced cancer, in addition to present physical and psychological distress, it needs to be assessed in all cases.”
ESMO (ESMO Open; Carrera et al.) 2024 · LoE: III
Why: Earnings often do not return to what they were, and late effects of treatment bring new costs.
“A risk-based approach necessitates tailored assessments, with frequency determined by factors such as the cancer stage, the risk of cancer recurrence and the potential for late complications, including secondary cancers.”
ESMO (ESMO Open; Carrera et al.) 2024 · LoE: III
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
The best-supported version is ESMO's 2024 expert consensus, the only society statement read that covers screening and management in more than one health system: assess financial impact at diagnosis or before treatment (LoE: V); as an approach it says still needs validation, use a simple question first and a longer validated questionnaire such as COST second; offer counselling from a dedicated professional who knows the local social security system (LoE: III); check benefit entitlements; assess every patient with far advanced cancer (LoE: III); and reassess after treatment by risk (LoE: III). ASCO's 2009 guidance statement adds that discussing the cost of care is part of high-quality care. The grades are low because the evidence is thin: no statement on practice is graded above III. The sources differ on the service to refer to. US practice has built financial navigation, and ESMO says that navigation "is most relevant to the United States setting"; the largest randomised trial of it read (CAFE, 371 participants) found no benefit over a list of resources, while a meta-analysis found benefit only in people with the worst scores. ESMO's own recommendation is counselling by a social worker and help with welfare entitlements, which is closer to UK benefits advice; no randomised trial of that model was found.
ESMO (ESMO Open; Carrera et al.) 2024 · ASCO, Journal of Clinical Oncology (Meropol et al.) 2009 · Cancer (de Souza et al.) 2017 · National Cancer Institute 2024 · JCO Oncology Practice (Henrikson et al.) 2025 · Cancer (Rashidi et al.) 2024
Where it differs: The problem is led by medical bills: premiums, deductibles, copayments and coinsurance, with high coinsurance for many oral cancer medicines. The response is a financial navigator or counsellor who works on insurance, assistance programmes and bills, alongside the cost conversation.
Evidence: The NCI summary (updated May 2024) reports that 1.7 per cent of cancer survivors filed for bankruptcy within 5 years of diagnosis, 2.7 times the rate of people without cancer; that about 60 per cent of people across studies had positive attitudes to cost discussions while fewer than one third had had one; and it states of the proposed interventions: "to date, there have been no prospective studies evaluating the impact of these interventions on the rates and severity of financial distress, care choices, quality of life, or survival". Since then the CAFE trial (371 people newly diagnosed, two integrated health systems) found financial hardship and quality of life at 12 months similar with brief or extended navigation and with enhanced usual care, in which every arm received a list of resources. A meta-analysis of four navigation studies (373 participants) found no significant pooled change in COST score (1.21; 95 per cent confidence interval, minus 6.54 to 8.96) but a significant change where the score before the intervention was 14.5 or lower. A single-arm study of 86 survivors in North Carolina, recruited with a COST score below 23, reported improved anxiety, depression and global mental health after navigation, with no comparison group.
National Cancer Institute 2024 · JCO Oncology Practice (Henrikson et al.) 2025 · Cancer (Rashidi et al.) 2024 · Psycho-Oncology (Waters et al.) 2026
Where it differs: The UK scoping review gives two main reasons for hardship: lost income, and extra non-medical costs such as special diet, heating, travel and car parking. The response is benefits and welfare rights advice, often from a charity: Macmillan's page tells people to call its money advisers and lists Universal Credit, sick pay, Personal Independence Payment, help with rent, the Healthcare Travel Costs Scheme and carers' benefits.
Evidence: A scoping review of 29 UK studies and reports (searched July 2022) found that most reported severe financial problems after diagnosis, with loss of income and extra spending as the main reasons, and that only two quantified them: a 2013 Macmillan report put households on average £570 a month worse off. The review states that "The validated questionnaire to investigate FT, COST, has not been used in any UK studies." It includes qualitative evaluations of a welfare rights advice service for people with cancer in County Durham, in which successful claims offset extra costs and reduced stress and anxiety about money; no UK randomised trial of benefits advice in cancer was found. The holistic needs assessment used in England is described in the distress screening protocol.
Journal of Public Health (Ngan et al.) 2023 · Macmillan Cancer Support 2025
Where it differs: Cancer care is largely free at the point of service, medicines for self-administration may carry a copayment with or without a cap, and sick pay and unemployment payments replace part of lost income. ESMO notes that some new medicines lack public funding and that travel and accommodation costs remain.
Evidence: A systematic review of 32 studies in countries with publicly funded care (Canada, Australia, Ireland, the UK, Germany, Denmark, Malaysia, Finland, France, South Korea and the Netherlands) found out-of-pocket costs of US$17 to US$506 a month, lost income of 17.6 to 67.3 per cent, and financial burden, distress or toxicity in 22 to 27 per cent, and concluded: "Despite government-funded universal public healthcare, financial toxicity is an issue for cancer patients and their families." ESMO's statement 3B (LoE: IV) says direct payments are probably modest under universal coverage but that non-medical and indirect costs remain.
Supportive Care in Cancer (Longo et al.) 2020 · ESMO (ESMO Open; Carrera et al.) 2024
Where it differs: A structured financial navigation programme for people with breast cancer in hospital, given in two core sessions with an optional third, with outcomes measured one and three months after discharge.
Evidence: A cluster randomised trial of 82 participants (41 per group) found an effect on subjective financial toxicity and on cost-related health literacy, and reported that "no significant effects were found on material and behavioral domains of FT". It is small, from one country, and its authors call the evidence preliminary.
Where it differs: A single item from a general quality of life questionnaire (item 28 of the EORTC QLQ-C30, or the financial item of the Edmonton Symptom Assessment System Total Care), or a dedicated measure: COST (United States, 12 items of which 11 are scored, 0 to 44, lower scores meaning more financial toxicity) or PROFFIT (Italy, 16 items).
Evidence: COST was developed with 155 patients with advanced cancer and validated in 233 patients with stage IV solid tumours on chemotherapy in the United States, all insured; it showed internal consistency (Cronbach alpha 0.92) and correlated with quality of life. ESMO describes the two-stage approach as one "which requires further validation". No cut-off score for referral is set by any guideline read.
ESMO (ESMO Open; Carrera et al.) 2024 · Cancer (de Souza et al.) 2017 · Cancer (de Souza et al.) 2014
Cancer often ruins families financially, and money worries make people skip treatment. Ask about finances at the first visit, as routinely as asking about allergies, and route people to assistance.
Help with the money side of cancer has been tested by offering it to every new patient, and the largest trial found it made no difference. A pooled analysis suggests it does help the people whose questionnaire scores show the most financial strain. A trial that screens first and gives the help only to that group would settle whether targeting is the way to make it work.
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Preliminary assessment of financial impact at diagnosis or before the start of treatment | LoE: V | ESMO (ESMO Open; Carrera et al.) 2024 |
| Offer financial counselling after screening to a patient with any form of financial toxicity “Thus, it is both ethically and medically reasonable to offer financial counselling to a patient suffering from any form of financial toxicity following screening for financial toxicity.” | LoE: III | ESMO (ESMO Open; Carrera et al.) 2024 |
| Avoid low-value diagnostics and therapeutics, and offer navigation into services “Navigation into services should be offered by relevant health care professionals.” | LoE: V | ESMO (ESMO Open; Carrera et al.) 2024 |
| In far advanced cancer, manage identified financial distress with counselling and help with welfare entitlements “When financial distress is identified, management approaches should include financial counselling, assistance with social welfare entitlements and mobilization of other strategies to cope with distress.” | LoE: III | ESMO (ESMO Open; Carrera et al.) 2024 |
| Include carers in survivorship care, with support for financial issues “Institutions need to include caregivers as important stakeholder in the survivorship care delivery model, ensuring optimal psychosocial support, including for financial issues, can help decrease the familial financial burden.” | LoE: III | ESMO (ESMO Open; Carrera et al.) 2024 |
| Under universal coverage direct payments are probably modest, but non-medical and indirect costs remain “Patients with cancer in publicly funded health systems may still face direct non-medical costs as well as indirect costs, some of which may be mitigated by coverage of benefits due to sickness, therapy and unemployment payment.” | LoE: IV | ESMO (ESMO Open; Carrera et al.) 2024 |
| The COST measure is reliable and valid for measuring financial toxicity (233 US patients with advanced cancer) “The COST measure demonstrated reliability and validity in measuring financial toxicity.” | validation study, n = 233 | Cancer (de Souza et al.) 2017 |
| Proactive financial navigation did not improve financial hardship or quality of life at 12 months against enhanced usual care “Financial navigation was not associated with improved financial hardship or cancer-related quality of life in patients newly diagnosed with cancer compared with enhanced usual care.” | randomised trial, n = 371 (283 at 12 months) | JCO Oncology Practice (Henrikson et al.) 2025 |
| Across 11 intervention studies financial worry improved in a minority; navigation helped people at highest risk “Financial worry improved in only 27.3% of 11 studies.” | systematic review and meta-analysis, 11 studies, 2211 participants | Cancer (Rashidi et al.) 2024 |
| Financial distress is linked to reduced adherence, lower quality of life and shorter survival in retrospective studies “Evidence from multiple retrospective studies shows that patients experiencing financial distress have reduced adherence to planned therapies, lower quality of life, and diminished survival.” | evidence summary, not graded | National Cancer Institute 2024 |
Shares Consent and education before anticancer treatment, Distress screening with the distress thermometer, and referral by need, End of treatment: treatment summary, survivorship care plan and handover to primary care, American Society of Clinical Oncology (ASCO) and the tag protocol.
Shares Screen every patient for financial hardship at diagnosis and connect them to help, Employment rights with cancer in the United States, Employment rights with cancer in the United Kingdom, Going back to work after cancer: the rates, and the programmes that change them and the tag psychosocial.
Shares European Society for Medical Oncology (ESMO), Quality of life and the tags protocol, supportive-care.
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO) and the tags protocol, supportive-care.
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO) and the tags protocol, supportive-care.
Shares European Society for Medical Oncology (ESMO) and the tags protocol, supportive-care.
Shares American Society of Clinical Oncology (ASCO) and the tags protocol, supportive-care.
Shares American Society of Clinical Oncology (ASCO) and the tags protocol, supportive-care.